ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,277.51
      0.80%
      US Tech 100
      18,064.80
      0.02%
      Dow Jones
      38,686.32
      1.51%
      Brent Oil
      81.295
      0.00%
      Bitcoin
      67,716.74
      -0.01%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. UroGen Pharma Ltd (URGN)

      7. UroGen Pharma Ltd (URGN) News

      URGN

      UroGen Pharma (URGN)

      UroGen Pharma Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:URGN
      DateTimeSourceHeadlineSymbolCompany
      05/22/20248:00AMBusiness WireUroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:URGNUroGen Pharma Ltd
      05/13/20248:05AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:URGNUroGen Pharma Ltd
      05/13/20248:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
      05/13/20248:00AMBusiness WireUroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business HighlightsNASDAQ:URGNUroGen Pharma Ltd
      05/07/20248:00AMBusiness WireUroGen Pharma to Participate at Upcoming Investor ConferencesNASDAQ:URGNUroGen Pharma Ltd
      05/05/202412:20PMBusiness WireNew Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction TherapyNASDAQ:URGNUroGen Pharma Ltd
      05/04/20243:20PMBusiness WireUroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024NASDAQ:URGNUroGen Pharma Ltd
      05/04/202411:50AMBusiness WireNew Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal TrialNASDAQ:URGNUroGen Pharma Ltd
      05/03/20248:00AMBusiness WireUroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024NASDAQ:URGNUroGen Pharma Ltd
      04/17/202412:02PMBusiness WireUroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial CancersNASDAQ:URGNUroGen Pharma Ltd
      04/15/20248:00AMBusiness WireUroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNASDAQ:URGNUroGen Pharma Ltd
      04/03/20248:00AMBusiness WireUroGen Pharma Files Patent Infringement Action Against Teva PharmaceuticalsNASDAQ:URGNUroGen Pharma Ltd
      03/14/20248:00AMBusiness WireUroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102NASDAQ:URGNUroGen Pharma Ltd
      03/08/20248:00AMBusiness WireUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:URGNUroGen Pharma Ltd
      03/04/20248:00AMBusiness WireUroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024NASDAQ:URGNUroGen Pharma Ltd
      03/04/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
      03/01/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
      02/26/20248:00AMBusiness WireUroGen Pharma to Present at TD Cowen 44th Annual Health Care ConferenceNASDAQ:URGNUroGen Pharma Ltd
      02/12/20245:47PMEdgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:URGNUroGen Pharma Ltd
      02/12/20245:43PMEdgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:URGNUroGen Pharma Ltd
      02/07/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
      02/05/20249:16PMEdgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:URGNUroGen Pharma Ltd
      02/05/20249:15PMEdgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:URGNUroGen Pharma Ltd
      02/02/20247:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
      02/02/20247:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
      02/02/20247:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
      02/02/20247:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
      02/01/202410:13AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:URGNUroGen Pharma Ltd
      02/01/20249:53AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:URGNUroGen Pharma Ltd
      02/01/20248:00AMBusiness WireUroGen Pharma to Participate at Upcoming Investor ConferencesNASDAQ:URGNUroGen Pharma Ltd
       Showing the most relevant articles for your search:NASDAQ:URGN